George Gibson, MD
Interventional Cardiology · Pueblo, CONPI 1205880960
Payments from drug & device makers
What this record shows
13 manufacturers reported payments, led by Edwards Lifesciences at 58.5% of the total. Reporting peaked in 2019 at $2,845 and has fallen 93.3% since, to $191 in 2025. That places this record below the midpoint for interventional cardiology clinicians in CO, where the typical reported total is $6,820.
Across 103 payments — averaging $66.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$4K
- Medtronic$1K
- Boston Scientific$799
- Abbott$492
- Pfizer$123
- Abiomed$39
- plus $154 from 7 others
What the payments were for
- Travel & lodging$3,84856%
- Food & beverage$2,97244%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 24 | $3,989 |
| Medtronic(2 entities) | 15 | $1,223 |
| Boston Scientific | 38 | $799 |
| Abbott | 15 | $492 |
| Pfizer | 1 | $123 |
| Abiomed | 1 | $39 |
| Johnson & Johnson | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Novo Nordisk | 1 | $21 |
| AstraZeneca | 1 | $19 |
| Novartis | 1 | $16 |
| W. L. Gore & Associates, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$3,520
- COREVALVE EVOLUT R$773
- PASCAL$159
- SYMPLICITY G3$155
- MitraClip$129
- VYNDAQEL$123
- GENERAL - THERAPIES$114
How this compares
$6,820 in reported general payments places this provider in the 50th percentile of 111 interventional cardiology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 353 | $420,382 |
| EntrestoSacubitril/Valsartan | 47 | $76,143 |
| JardianceEmpagliflozin | 40 | $64,421 |
| XareltoRivaroxaban | 33 | $49,297 |
| Repatha SureclickEvolocumab | 57 | $34,071 |
| FarxigaDapagliflozin Propanediol | 22 | $31,825 |
| Praluent PenAlirocumab | 11 | $9,809 |
| Metoprolol Succinate | 410 | $5,670 |
| Atorvastatin Calcium | 345 | $3,738 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 15 | $2,934 |
| PradaxaDabigatran Etexilate Mesylate | 13 | $2,009 |
| ClopidogrelClopidogrel Bisulfate | 145 | $1,908 |
| Lisinopril | 246 | $1,853 |
| Losartan Potassium | 171 | $1,565 |
| Carvedilol | 174 | $1,535 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $123 | $420,382353 claims |
| NovartisEntresto | $16 | $76,14347 claims |
| Johnson & JohnsonXarelto | $33 | $49,29733 claims |
| AstraZenecaFarxiga | $19 | $31,82522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 111 interventional cardiology providers in Colorado.
Other interventional cardiology in Pueblo
- Bhavith Aruni BabuPueblo$50K
- Derar AlbashairehPueblo$8K
- Ehrin ArmstrongEnglewood$718K
- Gareth MorganAurora$536K
- Jamaluddin MolooAurora$272K
- Jenny Zablah AlabiAurora$269K
- Srinivas IyengarBoulder$254K
- Nima AghiliLakewood$220K
- Sridhar Sampath-KumarAurora$142K
- Matthew ZipseAurora$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.